Patel Naimish 4
4 · CRISPR Therapeutics AG · Filed Mar 24, 2026
Research Summary
AI-generated summary of this filing
CRISPR Therapeutics CMO Naimish Patel Receives Awards
What Happened
Naimish Patel, Chief Medical Officer of CRISPR Therapeutics (CRSP), was granted two equity awards on March 20, 2026: a stock option covering 38,499 common shares and restricted stock units (RSUs) for 30,000 common shares. Both grants were reported as awards (code A) with a reported acquisition price of $0.00 (no cash paid at grant). Total potential shares from the awards: 68,499.
Key Details
- Transaction date: March 20, 2026 (Form 4 filed March 24, 2026 — filing was within the SEC’s 2-business-day window).
- Award breakdown: 38,499-share option (vests monthly in 48 equal installments; first vesting 4/20/2026); 30,000 RSUs (25% vest on each of 3/20/2027, 3/20/2028, 3/20/2029, 3/20/2030).
- Price/value reported: $0.00 per share at grant (no cash exchanged at grant).
- Lock-up: These shares remain subject to a lock-up agreement with the underwriters of the issuer’s offering of convertible senior notes due 2031.
- Shares owned after transaction: not specified in the provided filing details.
- Transaction code: A = Award/Grant (derivative awards: option and RSUs).
Context
These are standard compensation grants for an executive rather than open‑market purchases or sales. The option vests monthly over four years (after first monthly vest on 4/20/2026), and RSUs vest in four annual tranches. RSUs represent a contingent right to receive one share each upon vesting. Because the awards are subject to a lock-up tied to the convertible notes offering, Patel may be restricted from selling some granted shares until that lock-up expires.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1][F2]2026-03-20+38,499→ 38,499 totalExercise: $46.24Exp: 2036-03-20→ Common Shares (38,499 underlying) - Award
Restricted Stock Units
[F3][F1][F4]2026-03-20+30,000→ 30,000 total→ Common Shares (30,000 underlying)
Footnotes (4)
- [F1]These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031.
- [F2]This option was granted on March 20, 2026 with respect to 38,499 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 20, 2026.
- [F3]Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
- [F4]This restricted stock unit award was granted on March 20, 2026 with respect to 30,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2027 , (ii) one quarter of the shares vesting on March 20, 2028, (iii) one quarter of the shares vesting on March 20, 2029, and (iv) one quarter of the shares vesting on March 20, 2030.